drugset
drugset / Trial / NCT05652855

Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors

NCT05652855 ↗

Phase 1/2 Not yet recruiting 48 enrolled Minghui Pharmaceutical Pty Ltd
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety/tolerability, pharmacokinetics and efficacy of MHB088C in participants with advanced or metastatic solid tumors.

Timeline

Start
2023-01-23
Primary completion
2026-01-31
Completion
2026-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject MHB088C Monoclonal antibody — Intravenous

Indications

No indication recorded.